Leantor Capsule contains Orlistat 120 mg, a potent lipase inhibitor indicated for the management of obesity. It is prescribed as an adjunct to a reduced-calorie diet and increased physical activity in adult patients with a body mass index (BMI) of 30 kg/m² or greater, or 27 kg/m² with associated risk factors such as hypertension, diabetes, or dyslipidemia. Orlistat acts locally in the gastrointestinal tract by inhibiting pancreatic and gastric lipases, enzymes responsible for the hydrolysis of dietary triglycerides into absorbable free fatty acids and monoglycerides. By blocking lipase activity, Orlistat reduces fat absorption by approximately 30%, leading to decreased caloric intake and subsequent weight loss. Clinical studies have demonstrated that Leantor Capsule, when combined with lifestyle modifications, significantly improves weight reduction and associated metabolic parameters. Common adverse effects include gastrointestinal symptoms such as oily spotting, flatulence with discharge, and fecal urgency, which are generally mild and related to dietary fat intake. Patients are advised to adhere to a nutritionally balanced, reduced-fat diet to minimize side effects. Leantor Capsule should be used under medical supervision, with periodic monitoring of liver function and fat-soluble vitamin levels, as Orlistat may impair absorption of fat-soluble vitamins (A, D, E, K). It is contraindicated in pregnancy, chronic malabsorption syndromes, and cholestasis.